TISIDB

Summary
Symbol	MYO6
Name	myosin VI
Aliases	KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location	6q14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Golgi apparatus, trans-Golgi network membrane; Peripheral membrane protein. Golgi apparatus Nucleus. Cytoplasm, perinuclear region. Membrane, clathrin-coated pit. Cell projection, ruffle membrane; Peripheral membrane protein. Note=Also present in endocyctic vesicles, and membrane ruffles. Translocates from membrane ruffles, endocytic vesicles and cytoplasm to Golgi apparatus, perinuclear membrane and nucleus through induction by p53 and p53-induced DNA damage. Recruited into membrane ruffles from cell surface by EGF-stimulation. Colocalizes with DAB2 in clathrin-coated pits/vesicles. Colocalizes with OPTN at the Golgi complex and in vesicular structures close to the plasma membrane (By similarity). ; SUBCELLULAR LOCATION: Isoform 3: Cytoplasmic vesicle, clathrin-coated vesicle membrane.; SUBCELLULAR LOCATION: Isoform 4: Cytoplasmic vesicle, clathrin-coated vesicle membrane. Cell projection, ruffle membrane.
Domain	PF16521 Myosin VI cargo binding domain PF00063 Myosin head (motor domain)
Function	Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Myosin 6 is a reverse-direction motor protein that moves towards the minus-end of actin filaments. Has slow rate of actin-activated ADP release due to weak ATP binding. Functions in a variety of intracellular processes such as vesicular membrane trafficking and cell migration. Required for the structural integrity of the Golgi apparatus via the p53-dependent pro-survival pathway. Appears to be involved in a very early step of clathrin-mediated endocytosis in polarized epithelial cells. May act as a regulator of F-actin dynamics. May play a role in transporting DAB2 from the plasma membrane to specific cellular targets. Required for structural integrity of inner ear hair cells (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0007605 sensory perception of sound GO:0030048 actin filament-based movement GO:0030330 DNA damage response, signal transduction by p53 class mediator GO:0042493 response to drug GO:0042770 signal transduction in response to DNA damage GO:0050954 sensory perception of mechanical stimulus GO:0072331 signal transduction by p53 class mediator
Molecular Function	GO:0000146 microfilament motor activity GO:0003774 motor activity GO:0003779 actin binding GO:0005516 calmodulin binding GO:0043531 ADP binding GO:0045296 cadherin binding GO:0050839 cell adhesion molecule binding GO:0051015 actin filament binding GO:0060001 minus-end directed microfilament motor activity GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component	GO:0000428 DNA-directed RNA polymerase complex GO:0001726 ruffle GO:0005635 nuclear envelope GO:0005765 lysosomal membrane GO:0005884 actin filament GO:0005902 microvillus GO:0005905 clathrin-coated pit GO:0005913 cell-cell adherens junction GO:0005938 cell cortex GO:0015629 actin cytoskeleton GO:0016459 myosin complex GO:0016461 unconventional myosin complex GO:0016591 DNA-directed RNA polymerase II, holoenzyme GO:0030135 coated vesicle GO:0030136 clathrin-coated vesicle GO:0030139 endocytic vesicle GO:0030659 cytoplasmic vesicle membrane GO:0030662 coated vesicle membrane GO:0030665 clathrin-coated vesicle membrane GO:0030880 RNA polymerase complex GO:0031252 cell leading edge GO:0031253 cell projection membrane GO:0031256 leading edge membrane GO:0031941 filamentous actin GO:0031965 nuclear membrane GO:0032587 ruffle membrane GO:0045177 apical part of cell GO:0045334 clathrin-coated endocytic vesicle GO:0055029 nuclear DNA-directed RNA polymerase complex GO:0061695 transferase complex, transferring phosphorus-containing groups GO:0098589 membrane region GO:0098852 lytic vacuole membrane GO:0098858 actin-based cell projection GO:0099568 cytoplasmic region

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-190873: Gap junction degradation R-HSA-190828: Gap junction trafficking R-HSA-157858: Gap junction trafficking and regulation R-HSA-399721: Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity R-HSA-199991: Membrane Trafficking R-HSA-112316: Neuronal System R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell R-HSA-399719: Trafficking of AMPA receptors R-HSA-112315: Transmission across Chemical Synapses R-HSA-5653656: Vesicle-mediated transport

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-190873: Gap junction degradation
R-HSA-190828: Gap junction trafficking
R-HSA-157858: Gap junction trafficking and regulation
R-HSA-399721: Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
R-HSA-199991: Membrane Trafficking
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-399719: Trafficking of AMPA receptors
R-HSA-112315: Transmission across Chemical Synapses
R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	MYO6
Name	myosin VI
Aliases	KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location	6q14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MYO6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MYO6
Name	myosin VI
Aliases	KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location	6q14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MYO6 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MYO6
Name	myosin VI
Aliases	KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location	6q14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MYO6 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.019	0.954
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.415	0.692
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.341	0.651
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.44	0.203
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.435	0.848
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.444	0.874
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.255	0.585
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.034	0.471
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.553	0.718
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.693	0.558
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.524	0.778
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.046	0.651

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MYO6 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	0	14.3	0.196
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	20	0	20	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	2.7	12.1	0.0439
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	3.4	11.4	0.0746
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MYO6
Name	myosin VI
Aliases	KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location	6q14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYO6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MYO6
Name	myosin VI
Aliases	KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location	6q14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYO6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYO6. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MYO6
Name	myosin VI
Aliases	KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location	6q14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYO6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MYO6
Name	myosin VI
Aliases	KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location	6q14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MYO6 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MYO6
Name	myosin VI
Aliases	KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location	6q14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MYO6 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MYO6
Name	myosin VI
Aliases	KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location	6q14.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MYO6 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MYO6